ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
bearish•XtalPi
•10 Jun 2025 09:48

Xtalpi US$860m IPO Lockup Expiry - Last of the Lockup Release with Nearly All Shares in CCASS Now

XtalPi Holdings (2228 HK) was listed in Hong Kong on 13th Jun 2024 after raising US$126m. Its one-year lockup will expire soon.

Logo
1k Views
Share
•09 Jun 2025 11:25

Zhejiang Sanhua Intelligent Controls A/H Listing - PHIP Updates and Thoughts on A/H Premium

Zhejiang Sanhua Intellignt Controls Co., Ltd. (002050 CH) (ZSIC), a manufacturer of refrigeration and air-conditioning control components, aims to...

Logo
638 Views
Share
•04 Jun 2025 17:06

Jiangsu Hengrui Medicine (600276 CH): ADC Drug Approval Presents Long-Term Opportunity

​Jiangsu Hengrui receives conditional approval for Trastuzumab Rezetecan for NSCLC. In 1Q25, the company reported sales growth of 20%. Innovative...

Logo
545 Views
Share
•04 Jun 2025 09:55

Wuxi Lead Intelligent Equipment A/H Listing - Market Leader but Has Been Facing Industry Headwinds

Wuxi Lead Intelligent Equipmen (300450 CH)  aims to raise around US$400m in its H-share listing. In this note, we look at the company's past...

Logo
535 Views
Share
•27 May 2025 09:48

Foshan Haitian Flavouring A/H Listing - PHIP Updates and Thoughts on A/H Premium

Foshan Haitian Flavouring & Food (603288 CH), China’s leading condiments company, now aims to raise around US$1bn in its H-share listing. In this...

Logo
651 Views
Share
x